Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$20.88 - $35.19 $280,689 - $473,059
-13,443 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$29.0 - $47.27 $10,440 - $17,017
-360 Reduced 2.61%
13,443 $432,000
Q4 2021

Feb 10, 2022

SELL
$42.59 - $55.02 $136,373 - $176,174
-3,202 Reduced 18.83%
13,803 $615,000
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $252,289 - $407,108
5,204 Added 44.1%
17,005 $857,000
Q2 2021

Aug 12, 2021

SELL
$50.3 - $78.44 $2.04 Million - $3.18 Million
-40,518 Reduced 77.44%
11,801 $925,000
Q1 2021

May 14, 2021

BUY
$53.8 - $81.53 $2.81 Million - $4.27 Million
52,319 New
52,319 $2.99 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.